Skip to main content

Table 1 Clinical characteristics and co-morbidity of asthma patients before anti-IL5/IL5R and anti-IgE therapy

From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

Characteristics Anti-IL5/IL5R, n = 42 Anti-IgE, n = 22
  Reslizumab, Mepolizumab, Benralizumab Omalizumab
Time of use (months) 12.79 (3–29. SD 8.49) 49.41 (6–127. SD 35.34)
Age (years) 56 (32–73. SD 9.75) 48 (28–76. SD 10.67)
Women (number, (%)) 23 (55) 15 (68)
Smokers (number, (%)) 0 (0) 0 (0)
Ex-smokers (number, (%)) 12 (29) 2 (9)
Body mass index (kg/m2) 28.9 (16.9–39. SD 5.1) 27.7 (20.4–36.8. SD 4.1)
Nasal polyposis (number, (%)) 31 (74) 12 (55)
Chronic rhinosinusitis (CRSwNP or CRSsNP) (number, (%)) 39 (93) 18 (82)
Allergic rhinitis (number, (%)) 12 (29) 17 (77)
ASA intolerance (number, (%)) 9 (21) 5 (23)
Osteoporosis (number, (%)) 16 (38) 8 (36)
Hypertension (number, (%)) 20 (48) 8 (36)
Diabetes mellitus (number, (%)) 3 (7) 3 (14)
Hypothyroidism (number, (%)) 7 (17) 3 (14)
Coronary artery disease (number, (%)) 1 (2) 0 (0)
Gastroesophageal reflux disease (number, (%)) 10 (24) 10 (45)
Atrial fibrillation (number, (%)) 3 (7) 1 (5)
Positive skin prick test or elevated allergen specific serum IgE (number, (%)) 17 (40) 22 (100)
Pathological HRCT findings (number, (%)) a 30 (71) 14 (64)
Patients with daily use of OCS (number, (%)) b 30 (71) 10 (45)
Mean daily OCS dose before treatment (mg) 7.07 (0–40. SD 7.13) 4.82 (0–20. SD 6.50)
Courses of OCS before treatment c 4.21 (0–12. SD 2.75) 2.50 (0–6. SD 1.56)
Courses of antibiotics before treatment c 1.40 (0–5. SD 1.42) 0.95 (0–3. SD 0.93)
Emergency room visits before treatment c 0.62 (0–8. SD 1.51) 0.18 (0–1. SD 0.39)
Sick leaves before treatment c 0.93 (0–6. SD 1.72) 0.59 (0–4. SD 1.03)
Hospitalisations before treatment c 0.52 (0–8. SD 1.42) 0.45 (0–2. SD 0.66)
FEV1 (mean) before treatment (litres) 2.27 (0.99–4.18. SD 0.78) 2.83 (1.5–4.2. SD 0.86)
FVC (mean) before treatment (litres) 3.38 (1.71–5.25. SD 0.99) 3.82 (2.1–5.8. SD 0.85)
FEV1/FVC (mean) before treatment 0.67 (0.42–0.91. SD 0.12) 0.74 (0.48–0.91. SD 0.13)
Blood eosinophil count (mean) before treatment (E9/litre) 0.45 (0.03–1.84. SD 0.37) 0.43 (0–1.34. SD 0.41)
Exhaled nitric oxide (mean) (ppb) 28.17 (5–110. SD 28.98) 35.66 (5–123. SD 36.30)
Serum total IgE (mean) (kU/litre) 290.85 (8–4672. SD 786.18) 313.36 (14–720. SD 248.76)
ACT (mean) d 15.6 (8–23. SD 4.28) 13.4 (7–22. SD 4.82)
  1. adefined as HRCT (high resolution computed tomography) detected ground glass pattern, bronchiectasis, mucous plugs, atelectasis, nodularity or bronchial thickening
  2. bOCS = per oral corticosteroids
  3. cNumber due to asthma during the past 12 months before biological treatment initiation
  4. dACT = Asthma control test, maximal score 25 points